Presentation is loading. Please wait.

Presentation is loading. Please wait.

Taiwan 2000 Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5- fluorouracil (5-FU)-irinotecan (IRI)?

Published byRosaline Cameron Modified over 9 years ago

Similar presentations

Presentation on theme: "Taiwan 2000 Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5- fluorouracil (5-FU)-irinotecan (IRI)?"— Presentation transcript:

1 Taiwan 2000 Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5- fluorouracil (5-FU)-irinotecan (IRI)? Results of the PETACC 3 - EORTC 40993 -SAKK 60/00 trial comparing IRI / 5-FU/folinic acid (FA) to 5-FU/FA in stage II- III colon cancer (COC) patients A.D. Roth, P. Yan, D. Dietrich, R. Fiocca, G. Bodoky, R. Labianca, D. Cunningham, E. Van Cutsem, F. Bosman, S. Tejpar UGT1A1 ASCO 2008

2 Irinotecan PathwayCPT-11 CPT-11 APC NPC CYP3A4 CYP3A5 SN-38G UGT1A1 CES 2 CES2 SN-38 SN-38 TOP I death SN-38 ABCB1 P-gp CPT-11 ABCB1 P-gp

3 UGT1A1 ASCO 2008  UGT1A1 mediates the glucuronidation of bilirubin and other endogenous compounds (estradiol, arachidonic acid metabolites)  Moderate decrease in UGT1A1 activity => Gilbert’s syndrome  Severe decrease in UGT1A1 activity => Crigler-Najjar syndrome  UGT1A1 and other UGTs (1A6, 1A7, 1A9 and 1A10) are involved in the glucuronidation of SN-38  UGT1A1 also involved in the glucuronidation of many xenobiotics (codeine, acetaminophen, tolbutamide and several statins) Function of UGT1A1

4 UGT1A1 ASCO 2008 UGT1A Gene Cluster TATATATATA=(TA) 5 TATATATATATA=(TA) 6 = *1 (WT) TATATATATATATA=(TA) 7 =*28 TATATATATATATATA=(TA) 8 …(TA) n … UGT1A: 17 alleles (different Exon 1’s)

5 UGT1A1 ASCO 2008 Author n/N (%) Est. Odds Ratio**95% CI 7/76/6 + 6/7 Carlini a 0/6 (0%) 21/58 (36%)-- Innocenti3/6 (50%)3/53 (6%)16.72.3 – 120.6 Marcuello b 1/10 (10%)2/85 (2%)4.60.4 – 56.0 Rouits4/7 (57%)10/66 (15%)7.51.4 – 38.5 Ando c 4/7 (57%) 22/111 (20%) 5.41.1 – 25.9 NCCTG 9741* 2/11 (18.2%)9/98 (8.8%)1.660.15 - 18.19 a Gr 3 or 4 diarrhea or neutropenia b Gr 4 values from personal communication. Published values are 3+. C Gr 4 leukopenia and/or Gr 3+ diarrhea. * ASCO 2006 #3520, IFL regimen **Unadjusted Odds Ratio Published Data on UGT1A1 & Grade 4 Neutropenia

6 UGT1A1 ASCO 2008 Objectives To assess the impact of UGT1A1 7/7 genotype compared to the 6/6 and 6/7 genotypes on the occurrence of severe toxicity attributable to FOLFIRI in a large population of colon cancer patients

7 UGT1A1 ASCO 2008 Methods DNA was extracted with phenol/chloroform from normal and tumoral tissues after microdissection of formol fixed paraffin embeded sections UGT1A1 genotype was assessed by PCR and fragment sizing on Normal DNA Patients were all treated by FOLFIRI for up to 24 weeks divided in 4 cycles of 6 weeks

8 UGT1A1 ASCO 2008 Statistics Frequency of toxicity according to UGT1A1 genotype status (6/6,6/7 or 7/7) was assessed by chi-square or Fisher’s exact tests Frequency trends of toxicity over 6/6, 6/7 and 7/7 were examined by Cochran-Armitage trend tests Multiple logistic regression was used to test the impact of other variables on toxicity outcomes Associations between two categorical variables were examined by chi-square or Fisher’s exact tests Multiple logistic regression was used to test the impact of other variables on toxicity outcomes and on occurence of dose reductions

9 UGT1A1 ASCO 2008 UGT1A1 Genotype frequency Genotypes Patient number Proportion A6/A658243.6% A6/A757443.0% A7/A716712.51% A5/A650.37% A5/A730.22% A6/A820.15% A7/A820.15% 1335 of 1405 samples (95%) with a result

10 UGT1A1 ASCO 2008 Neutropenia grade 4 per arm (cycles 1-3) Arm A (CPT-11) Patient #, (%) Arm B (Control) Patient #, (%) 6/6-6/7 237/540 (6.8%)13/546 (2.4%) 7/7 13/86 (15.1%)1/74 (1.3%) Arm A: p<0.009 (chi-square Test), Odds Ratio: 2.42 (95%CI: 1.23-4.77) Arm B: p=1.0 (Fisher’s Exact Test)

11 UGT1A1 ASCO 2008 Febrile Neutropenia per arm (cycles 1-3) Arm A (CPT-11) Patient #, (%) Arm B (Control) Patient #, (%) 6/6-6/7 23/546 (4.2%)9/546 (1.6%) 7/7 10/86 (11.7%)2/74 (2.7%) Arm A: p<0.009 (Fisher’s Exact Test), Odds Ratio: 2.99 (95%CI: 1.37-6.52) Arm B: p=0.63 (Fisher’s Exact Test)

12 UGT1A1 ASCO 2008 Grade 4 neutropenia (cycles 1-3): Multivariate logistic regression analysis and Odds Ratio Estimates Effect Wald Chi- Square Pr > Chi-Sq. OR Estimate (95% CI) Bilirubin0.04880.821.07 (0.55-2.11) Body surface area 0.69420.400.92 (0.76-1.11) Age +/- 60y 3.78820.0521.87 (0.99-3.50) Sex5.57610.01822.55 (1.17-5.58) Performance status 6.26390.01232.27 (1.19-4.32) UGT1A1 7/7 5.86550.01542.60 (1.20-5.64)

13 UGT1A1 ASCO 2008 Grade 4 neutropenia (cycles 1): Multivariate logistic regression analysis and Odds Ratio Estimates Effect Wald Chi- Square Pr > Chi-Sq. OR Estimate (95% CI) Bilirubin0.02570.871.07 (0.45-2.53) Body surface area 0.06420.801.03 (0.81-1.31) Age +/- 60y 1.25160.261.57 (0.71-3.46) Sex7.60960.00584.31 (1.52-12.1) Performance status 2.34500.121.90 (0.83-4.32) UGT1A1 7/7 3.17020.0752.46 (0.91-6.62)

14 UGT1A1 ASCO 2008 Probabilities to develop grade 4 neutropenia according to sex and UGT1A1 status (From the logistic regression model) Probabilities (95% CI) Cycle 1 Probabilities (95% CI) Cycles 1-3 Male not 7/7 0.013 (0.005-0.035)0.036 (0.020-0.065) Male, 7/7 0.067 (0.025-0.167)0.101 (0.046-0.208) Female not 7/7 0.075 (0.047-0.115)0.107 (0.074-0.153) Female, 7/7 0.115 (0.037-0.302)0.259 (0.128-0.452)

15 UGT1A1 ASCO 2008 Dose reductions (cycle 1) Multivariate logistic regression analysis Summary of Backward Elimination Effect Wald Chi-Square Pr > Chi-Sq. Bilirubin4.26210.039 Body surface area 0.34820.55 Age +/- 60y 0.94000.33 Sex15.8625<0.0001 Performance status 1.67440.19 UGT1A1 7/7 1.44970.22

16 UGT1A1 ASCO 2008 Dose reductions (cycles 1-3) Multivariate logistic regression analysis Summary of Backward Elimination Effect Wald Chi-Square Pr > Chi-Sq. Bilirubin0.03940.84 Body surface area 2.07920.15 Age +/- 60y 5.140.0233 Sex16.9708<0.0001 Performance status 1.71320.40 UGT1A1 7/7 0.96670.32

17 UGT1A1 ASCO 2008 Discussion UGT1A1 7/7 increases the incidence of grade 4 neutropenia and febrile neutropenia of FOLFIRI In multivariate LR analysis, sex is a much stronger predictor of grade 4 neutropenia than UGT1A1 during the first cycle of treatment and stays as a significant factor despite of dose reductions when 3 cycles of treatment were considered In multivariate analysis, female sex was strongly associated to dose reductions while UGT1A1 was not.

18 UGT1A1 ASCO 2008 Conclusion Female sex is a stronger predictor of grade 4 neutropenia than UGT1A1 7/7

Download ppt "Taiwan 2000 Is UGT1A1*28 homozygosity the strongest predictor for severe hematotoxicity in patients treated with 5- fluorouracil (5-FU)-irinotecan (IRI)?"

Similar presentations

Two-sample tests. Binary or categorical outcomes (proportions) Outcome Variable Are the observations correlated?Alternative to the chi- square test if.

Two-sample tests. Binary or categorical outcomes (proportions) Outcome Variable Are the observations correlated?Alternative to the chi- square test if.
Departments of Medicine and Biostatistics

Departments of Medicine and Biostatistics
Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan / 5-fluorouracil.

Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan / 5-fluorouracil.
Syphilis and HIV screening initiatives in North Carolina jails Lynne A. Sampson PhD, MPH HIV/STD Update September 25, 2008.

Syphilis and HIV screening initiatives in North Carolina jails Lynne A. Sampson PhD, MPH HIV/STD Update September 25, 2008.
Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,

Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,

Pilot Experience with Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer – NCCTG Intergroup N0147 J. Huang*, D. J. Sargent*,
April 25 Exam April 27 (bring calculator with exp) Cox-Regression

April 25 Exam April 27 (bring calculator with exp) Cox-Regression
Logistic Regression Multivariate Analysis. What is a log and an exponent? Log is the power to which a base of 10 must be raised to produce a given number.

Logistic Regression Multivariate Analysis. What is a log and an exponent? Log is the power to which a base of 10 must be raised to produce a given number.
BIOST 536 Lecture 3 1 Lecture 3 – Overview of study designs Prospective/retrospective  Prospective cohort study: Subjects followed; data collection in.

BIOST 536 Lecture 3 1 Lecture 3 – Overview of study designs Prospective/retrospective  Prospective cohort study: Subjects followed; data collection in.
Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.

Chapter 11 Survival Analysis Part 2. 2 Survival Analysis and Regression Combine lots of information Combine lots of information Look at several variables.
EPI 809/Spring 20081 Multiple Logistic Regression.

EPI 809/Spring Multiple Logistic Regression.
Sample Size Determination

Sample Size Determination
Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.

Introduction DCDOH supports HIV test and treat activities - increased number of HIV tests performed, emphasis on earlier linkage to care. Limited data.
David Yens, Ph.D. NYCOM PASW-SPSS STATISTICS David P. Yens, Ph.D. New York College of Osteopathic Medicine, NYIT l PRESENTATION.

David Yens, Ph.D. NYCOM PASW-SPSS STATISTICS David P. Yens, Ph.D. New York College of Osteopathic Medicine, NYIT l PRESENTATION.
Multiple Choice Questions for discussion

Multiple Choice Questions for discussion
Taiwan 2000 PETACC 3 ASCO 2009 Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC.

Taiwan 2000 PETACC 3 ASCO 2009 Molecular markers in colon cancer have a stage specific prognostic value. Results of the translational study on the PETACC.
Www.OncologyEducation.ca Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.
CHP400: Community Health Program - lI Research Methodology. Data analysis Hypothesis testing Statistical Inference test t-test and 22 Test of Significance.

CHP400: Community Health Program - lI Research Methodology. Data analysis Hypothesis testing Statistical Inference test t-test and 22 Test of Significance.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.

INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.

Similar presentations

Ads by Google